These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7862876)

  • 21. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers.
    von Bahr C; Wiesel FA; Movin G; Eneroth P; Jansson P; Nilsson L; Ogenstad S
    Psychopharmacology (Berl); 1991; 103(4):443-8. PubMed ID: 1676524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man.
    Ur E; Wright DM; Bouloux PM; Grossman A
    Br J Pharmacol; 1997 Mar; 120(5):781-4. PubMed ID: 9138682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion.
    Mota A; Bento A; Peñalva A; Pombo M; Dieguez C
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1973-7. PubMed ID: 7775648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-invasive assessment of selective 5-HT(1B/1D)-receptor agonist-induced peripheral vascular effects in humans: comparison of different techniques.
    Vanmolkot FH; de Hoon JN; Barrington P; Peck RW; Dallow NS; Williams PM; McColm J
    Eur J Clin Pharmacol; 2002 Aug; 58(5):303-8. PubMed ID: 12185552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects.
    van Berckel BN; Lipsch C; Timp S; Gispen-de Wied C; Wynne H; van Ree JM; Kahn RS
    Neuropsychopharmacology; 1997 May; 16(5):317-24. PubMed ID: 9109102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo drug action of tandospirone at 5-HT1A receptor examined using positron emission tomography and neuroendocrine response.
    Nakayama T; Suhara T; Okubo Y; Ichimiya T; Yasuno F; Maeda J; Takano A; Saijo T; Suzuki K
    Psychopharmacology (Berl); 2002 Dec; 165(1):37-42. PubMed ID: 12474116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of age on the GH response to sumatriptan administration in man.
    Coiro V; Volpi R; Davoli C; Caffarri G; Chiodera P
    J Neural Transm Gen Sect; 1995; 101(1-3):195-200. PubMed ID: 8695049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
    Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
    J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sumatriptan-induced growth hormone release in patients with major depression, mania, and normal controls.
    Yatham LN; Zis AP; Lam RW; Tam E; Shiah IS
    Neuropsychopharmacology; 1997 Oct; 17(4):258-63. PubMed ID: 9326750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine response to clomipramine and desipramine--the evidence of partial determination by heredity and sex.
    Filip V; Alda M; David I; Topinka J; Kristofiková Z; Dvoráková J; Sztaniszláv D; Olájos S; Albrecht V
    Neuropsychobiology; 1989; 21(3):111-6. PubMed ID: 2615927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormal 5-HT1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan.
    Cleare AJ; Murray RM; Sherwood RA; O'Keane V
    Psychol Med; 1998 Mar; 28(2):295-300. PubMed ID: 9572087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans.
    Monteleone P; Beinat L; Tanzillo C; Maj M; Kemali D
    Neuroendocrinology; 1990 Sep; 52(3):243-8. PubMed ID: 2170852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose citalopram as a 5-HT neuroendocrine probe.
    Attenburrow MJ; Mitter PR; Whale R; Terao T; Cowen PJ
    Psychopharmacology (Berl); 2001 May; 155(3):323-6. PubMed ID: 11432696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine and monoaminergic responses to acute administration of alprazolam in normal subjects.
    Zemishlany Z; McQueeney R; Gabriel SM; Davidson M
    Neuropsychobiology; 1990-1991; 23(3):124-8. PubMed ID: 2098668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests.
    Henning J; Netter P
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):67-71. PubMed ID: 14609009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of different serotonin receptor subtypes on growth hormone secretion.
    Valverde I; Penalva A; Dieguez C
    Neuroendocrinology; 2000 Feb; 71(2):145-53. PubMed ID: 10686528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects.
    Broocks A; Meyer T; Gleiter CH; Hillmer-Vogel U; George A; Bartmann U; Bandelow B
    Psychopharmacology (Berl); 2001 May; 155(3):234-41. PubMed ID: 11432685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of 5-HT(1B/1D) and 5-HT2A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries.
    Ellwood AJ; Curtis MJ
    Br J Pharmacol; 1997 Nov; 122(5):875-84. PubMed ID: 9384503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys.
    Aloi JA; Insel TR; Mueller EA; Murphy DL
    Life Sci; 1984 Apr; 34(14):1325-31. PubMed ID: 6708733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of oral racemic citalopram on neuroendocrine responses.
    Hawken ER; Owen JA; Van Vugt D; Delva NJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):694-700. PubMed ID: 16563590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.